Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/12 08:29:39 pm
172.56 USD   -0.12%
09:04a ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment T..
12/08 TEVA CONSIDERIN : Bloomberg
12/08 TEVA CONSIDERIN : Bloomberg
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 167.8, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The underlying tendency is negative on the weekly chart below the resistance at 206.75 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ALLERGAN PLC-21.49%57 457
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN18.98%128 363
SANOFI-4.84%109 438
BRISTOL-MYERS SQUIBB COMPAN..5.82%103 145
NOVO NORDISK A/S29.17%102 404
BAYER5.62%102 387
ABBOTT LABORATORIES42.38%95 629
ELI LILLY AND COMPANY16.75%95 432
GLAXOSMITHKLINE-17.57%85 531
CELGENE CORPORATION-11.25%85 030
ASTRAZENECA7.81%82 666
More Results
Financials ($)
Sales 2017 15 894 M
EBIT 2017 7 658 M
Net income 2017 -5 870 M
Debt 2017 24 765 M
Yield 2017 1,66%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,17x
EV / Sales 2018 5,13x
Capitalization 57 457 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ALLERGAN PLC
Duration : Period : Day
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Duration : Period : Week
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders